tislelizumab in combination with cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone

DRUG2 trials

Sponsors

The Affiliated Hospital of Xuzhou Medical University

Conditions

Angioimmunoblastic T-Cell Lymphoma RecurrentAngioimmunoblastic T-Cell Lymphoma RefractoryNew Diagnosed Angioimmunoblastic T-Cell Lymphoma

Phase 2

Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL

RecruitingNCT07058103

The Affiliated Hospital of Xuzhou Medical UniversityAngioimmunoblastic T-Cell Lymphoma Recurrent, Angioimmunoblastic T-Cell Lymphoma Refractory

Start: 2025-04-01End: 2028-04-01Target: 40Updated: 2025-07-10

Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITL

RecruitingNCT07168317

The Affiliated Hospital of Xuzhou Medical UniversityNew Diagnosed Angioimmunoblastic T-Cell Lymphoma

Start: 2025-08-01End: 2028-08-01Target: 40Updated: 2025-09-11